Why this matters
An SBOM is only as valuable as your ability to keep it accurate and act on it. The FDA's February 2026 guidance recommends a machine-readable SBOM and a device-specific assessment of known vulnerabilities. Section 524B requires a postmarket vulnerability plan for covered submissions. Daily monitoring and VEX are
Blue Goat Cyber℠ implementation choices, not FDA-prescribed requirements. This field guide is the operating manual: which tools, which formats, which workflows, and where teams typically fail.
Key takeaway: The most common SBOM failure mode is not technical - it's organizational. No single owner, no daily monitoring cadence, no VEX discipline. Fix the operating model first; tools second.